Case reports: Could sexual dysfunction in women with migraine be a side effect of CGRP inhibition?

IF 5 2区医学 Q1 CLINICAL NEUROLOGY

Cephalalgia Pub Date : 2024-05-01 DOI:10.1177/03331024241248837

Linda Al-Hassany, Deirdre M Boucherie, Emile G M Couturier, Antoinette MaassenVanDenBrink

{"title":"Case reports: Could sexual dysfunction in women with migraine be a side effect of CGRP inhibition?","authors":"Linda Al-Hassany, Deirdre M Boucherie, Emile G M Couturier, Antoinette MaassenVanDenBrink","doi":"10.1177/03331024241248837","DOIUrl":null,"url":null,"abstract":"Background: The development and approval of antibodies targeting calcitonin gene-related peptide or its receptor mark a revolutionary era for preventive migraine treatment. Real-world evidence sheds light on rare, stigmatized or overlooked side effects of these drugs. One of these potential side effects is sexual dysfunction.Case reports: We present two cases of one 42-year-old and one 45-year-old female patient with chronic migraine who both reported sexual dysfunction as a possible side effect of treatment with galcanezumab, a monoclonal antibody targeting calcitonin gene-related peptide.Discussion: As calcitonin gene-related peptide is involved in vaginal lubrication as well as genital sensation and swelling, inhibiting the calcitonin gene-related peptide pathway may lead to sexual dysfunction as a potential side effect.Conclusion: Sexual dysfunction in female migraine patients might be a rare and overlooked side effect of monoclonal antibodies targeting the calcitonin gene-related peptide pathway. Considering the discomfort and stigma surrounding both migraine and sexual dysfunction, we advocate for an open attitude and awareness among clinicians toward such side effects.","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 5","pages":"3331024241248837"},"PeriodicalIF":5.0000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cephalalgia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03331024241248837","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The development and approval of antibodies targeting calcitonin gene-related peptide or its receptor mark a revolutionary era for preventive migraine treatment. Real-world evidence sheds light on rare, stigmatized or overlooked side effects of these drugs. One of these potential side effects is sexual dysfunction.

Case reports: We present two cases of one 42-year-old and one 45-year-old female patient with chronic migraine who both reported sexual dysfunction as a possible side effect of treatment with galcanezumab, a monoclonal antibody targeting calcitonin gene-related peptide.

Discussion: As calcitonin gene-related peptide is involved in vaginal lubrication as well as genital sensation and swelling, inhibiting the calcitonin gene-related peptide pathway may lead to sexual dysfunction as a potential side effect.

Conclusion: Sexual dysfunction in female migraine patients might be a rare and overlooked side effect of monoclonal antibodies targeting the calcitonin gene-related peptide pathway. Considering the discomfort and stigma surrounding both migraine and sexual dysfunction, we advocate for an open attitude and awareness among clinicians toward such side effects.

查看原文本刊更多论文

病例报告：偏头痛女性患者的性功能障碍可能是 CGRP 抑制剂的副作用吗？

背景：针对降钙素基因相关肽或其受体的抗体的开发和批准标志着预防性偏头痛治疗进入了一个革命性的时代。现实世界的证据揭示了这些药物罕见的、被污名化或被忽视的副作用。其中一个潜在的副作用就是性功能障碍：我们报告了两个病例：一名 42 岁和一名 45 岁的女性慢性偏头痛患者都报告了性功能障碍，这可能是使用 galcanezumab（一种靶向降钙素基因相关肽的单克隆抗体）治疗的副作用：讨论：由于降钙素基因相关肽参与阴道润滑以及生殖器感觉和肿胀，抑制降钙素基因相关肽通路可能导致性功能障碍这一潜在副作用：女性偏头痛患者的性功能障碍可能是针对降钙素基因相关肽途径的单克隆抗体的一种罕见且被忽视的副作用。考虑到偏头痛和性功能障碍给患者带来的不适感和耻辱感，我们主张临床医生对此类副作用持开放态度并提高警惕。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cephalalgia 医学-临床神经学

CiteScore

10.10

自引率

6.10%

发文量

108

审稿时长

4-8 weeks

期刊介绍： Cephalalgia contains original peer reviewed papers on all aspects of headache. The journal provides an international forum for original research papers, review articles and short communications. Published monthly on behalf of the International Headache Society, Cephalalgia''s rapid review averages 5 ½ weeks from author submission to first decision.